{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T11:02:04Z","timestamp":1779793324712,"version":"3.53.1"},"reference-count":112,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"DOI":"10.1007\/s11886-026-02379-z","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T09:16:20Z","timestamp":1779786980000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Updates on Pathophysiology of Pericarditis to Guide Development of Therapeutics"],"prefix":"10.1007","volume":"28","author":[{"given":"Aldo","family":"Bonaventura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Vecchi\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adolfo Gabriele","family":"Mauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco Giuseppe","family":"Del Buono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany N.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Toldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Abbate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"2379_CR1","doi-asserted-by":"publisher","first-page":"3952","DOI":"10.1093\/eurheartj\/ehaf192","volume":"46","author":"J Schulz-Menger","year":"2025","unstructured":"Schulz-Menger J, Collini V, Groschel J, Adler Y, Brucato A, Christian V, et al. 2025 ESC Guidelines for the management of myocarditis and pericarditis. Eur Heart J. 2025;46:3952\u20134041.","journal-title":"Eur Heart J"},{"key":"2379_CR2","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.jcmg.2024.04.010","volume":"17","author":"AL Klein","year":"2024","unstructured":"Klein AL, Wang TKM, Cremer PC, Abbate A, Adler Y, Asher C, et al. Pericardial Diseases: International Position Statement on New Concepts and Advances in Multimodality Cardiac Imaging. JACC Cardiovasc Imaging. 2024;17:937\u201388.","journal-title":"JACC Cardiovasc Imaging"},{"key":"2379_CR3","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jacc.2019.11.021","volume":"75","author":"JG Chiabrando","year":"2020","unstructured":"Chiabrando JG, Bonaventura A, Vecchie A, Wohlford GF, Mauro AG, Jordan JH, et al. Management of Acute and Recurrent Pericarditis: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75:76\u201392.","journal-title":"J Am Coll Cardiol"},{"key":"2379_CR4","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.amjcard.2021.08.048","volume":"160","author":"MG Del Buono","year":"2021","unstructured":"Del Buono MG, Vecchie A, Damonte JI, Chiabrando JG, Dell MS, Bonaventura A, et al. Pericarditis Recurrence After Initial Uncomplicated Clinical Course. Am J Cardiol. 2021;160:112\u20136.","journal-title":"Am J Cardiol"},{"key":"2379_CR5","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1097\/FJC.0000000000001435","volume":"83","author":"GK Thomas","year":"2024","unstructured":"Thomas GK, Bonaventura A, Vecchie A, van Tassell B, Imazio M, Klein A, et al. Interleukin-1 Blockers for the Treatment of Recurrent Pericarditis: Pathophysiology, Patient-Reported Outcomes, and Perspectives. J Cardiovasc Pharmacol. 2024;83:503\u201310.","journal-title":"J Cardiovasc Pharmacol"},{"key":"2379_CR6","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.ijcard.2018.05.128","volume":"270","author":"A Mager","year":"2018","unstructured":"Mager A, Berger D, Ofek H, Hammer Y, Iakobishvili Z, Kornowski R. Prodromal symptoms predict myocardial involvement in patients with acute idiopathic pericarditis. Int J Cardiol. 2018;270:197\u20139.","journal-title":"Int J Cardiol"},{"key":"2379_CR7","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.ijcard.2012.09.052","volume":"168","author":"M Imazio","year":"2013","unstructured":"Imazio M, Hoit BD. Post-cardiac injury syndromes. An emerging cause of pericardial diseases. Int J Cardiol. 2013;168:648\u201352.","journal-title":"Int J Cardiol"},{"key":"2379_CR8","first-page":"100068","volume":"12","author":"J Malik","year":"2021","unstructured":"Malik J, Zaidi SMJ, Rana AS, Haider A, Tahir S. Post-cardiac injury syndrome: An evidence-based approach to diagnosis and treatment. Am Heart J Plus. 2021;12:100068.","journal-title":"Am Heart J Plus"},{"key":"2379_CR9","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jacbts.2020.11.016","volume":"6","author":"AG Mauro","year":"2021","unstructured":"Mauro AG, Bonaventura A, Vecchie A, Mezzaroma E, Carbone S, Narayan P, et al. The Role of NLRP3 Inflammasome in Pericarditis: Potential for Therapeutic Approaches. JACC Basic Transl Sci. 2021;6:137\u201350.","journal-title":"JACC Basic Transl Sci"},{"key":"2379_CR10","doi-asserted-by":"publisher","first-page":"261","DOI":"10.23736\/S0031-0808.21.04210-5","volume":"63","author":"A Vecchie","year":"2021","unstructured":"Vecchie A, Dell M, Mbualungu J, Ho AC, Vant B, Abbate A. Recurrent pericarditis: an update on diagnosis and management. Panminerva Med. 2021;63:261\u20139.","journal-title":"Panminerva Med"},{"key":"2379_CR11","doi-asserted-by":"publisher","first-page":"5390","DOI":"10.1002\/jcp.27436","volume":"234","author":"A Bonaventura","year":"2019","unstructured":"Bonaventura A, Montecucco F. Inflammation and pericarditis: Are neutrophils actors behind the scenes? J Cell Physiol. 2019;234:5390\u20138.","journal-title":"J Cell Physiol"},{"key":"2379_CR12","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1097\/FJC.0000000000001553","volume":"83","author":"A Vecchie","year":"2024","unstructured":"Vecchie A, Bonaventura A, Golino M, Thomas G, Abbate A. Novel Therapeutic Insights Into the Treatment of Pericarditis: Targeting the Innate Immune System. J Cardiovasc Pharmacol. 2024;83:377\u201383.","journal-title":"J Cardiovasc Pharmacol"},{"key":"2379_CR13","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1161\/CIRCRESAHA.120.315937","volume":"126","author":"A Abbate","year":"2020","unstructured":"Abbate A, Toldo S, Marchetti C, Kron J, Van Tassell BW, Dinarello CA. Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease. Circ Res. 2020;126:1260\u201380.","journal-title":"Circ Res"},{"key":"2379_CR14","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1001\/jama.2016.15826","volume":"316","author":"A Brucato","year":"2016","unstructured":"Brucato A, Imazio M, Gattorno M, Lazaros G, Maestroni S, Carraro M, et al. Effect of Anakinra on Recurrent Pericarditis Among Patients With Colchicine Resistance and Corticosteroid Dependence: The AIRTRIP Randomized Clinical Trial. JAMA. 2016;316:1906\u201312.","journal-title":"JAMA"},{"key":"2379_CR15","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1056\/NEJMoa2027892","volume":"384","author":"AL Klein","year":"2021","unstructured":"Klein AL, Imazio M, Cremer P, Brucato A, Abbate A, Fang F, et al. Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis. N Engl J Med. 2021;384:31\u201341.","journal-title":"N Engl J Med"},{"key":"2379_CR16","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jacc.2023.04.046","volume":"82","author":"VY Myachikova","year":"2023","unstructured":"Myachikova VY, Maslyanskiy AL, Moiseeva OM, Vinogradova OV, Gleykina EV, Lavrovsky Y, et al. Treatment of Idiopathic Recurrent Pericarditis With Goflikicept: Phase II\/III Study Results. J Am Coll Cardiol. 2023;82:30\u201340.","journal-title":"J Am Coll Cardiol"},{"key":"2379_CR17","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1016\/j.jacc.2025.05.023","volume":"86","author":"TKM Wang","year":"2025","unstructured":"Wang TKM, Klein AL, Cremer PC, Imazio M, Kohnstamm S, Luis SA, et al. 2025 Concise Clinical Guidance: An ACC Expert Consensus Statement on the Diagnosis and Management of Pericarditis: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2025;86:2691\u2013719.","journal-title":"J Am Coll Cardiol"},{"key":"2379_CR18","doi-asserted-by":"publisher","first-page":"77","DOI":"10.31083\/j.rcm2403077","volume":"24","author":"A Bonaventura","year":"2023","unstructured":"Bonaventura A, Thomas GK, Golino M, Mauro AG, Vecchie A, Del Buono MG, et al. Novel Pathophysiological, Diagnostic and Therapeutic Concepts in Acute and Recurrent Pericarditis. Rev Cardiovasc Med. 2023;24:77.","journal-title":"Rev Cardiovasc Med"},{"key":"2379_CR19","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/path.1711310202","volume":"131","author":"A Matsumori","year":"1980","unstructured":"Matsumori A, Kawai C. Coxsackie virus B3 perimyocarditis in BALB\/c mice: experimental model of chronic perimyocarditis in the right ventricle. J Pathol. 1980;131:97\u2013106.","journal-title":"J Pathol"},{"key":"2379_CR20","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/S0735-1097(86)80429-6","volume":"8","author":"PL Page","year":"1986","unstructured":"Page PL, Plumb VJ, Okumura K, Waldo AL. A new animal model of atrial flutter. J Am Coll Cardiol. 1986;8:872\u20139.","journal-title":"J Am Coll Cardiol"},{"key":"2379_CR21","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1002\/aja.1001800408","volume":"180","author":"LV Leak","year":"1987","unstructured":"Leak LV, Ferrans VJ, Cohen SR, Eidbo EE, Jones M. Animal model of acute pericarditis and its progression to pericardial fibrosis and adhesions: ultrastructural studies. Am J Anat. 1987;180:373\u201390.","journal-title":"Am J Anat"},{"key":"2379_CR22","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.1161\/01.CIR.0000147538.92263.3A","volume":"110","author":"M Afanasyeva","year":"2004","unstructured":"Afanasyeva M, Georgakopoulos D, Fairweather D, Caturegli P, Kass DA, Rose NR. Novel model of constrictive pericarditis associated with autoimmune heart disease in interferon-gamma-knockout mice. Circulation. 2004;110:2910\u20137.","journal-title":"Circulation"},{"key":"2379_CR23","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13019-019-0940-9","volume":"14","author":"A Kojima","year":"2019","unstructured":"Kojima A, Sakaue T, Okazaki M, Shikata F, Kurata M, Imai Y, et al. A simple mouse model of pericardial adhesions. J Cardiothorac Surg. 2019;14:124.","journal-title":"J Cardiothorac Surg"},{"key":"2379_CR24","doi-asserted-by":"publisher","first-page":"8061","DOI":"10.4049\/jimmunol.0902477","volume":"183","author":"H Kumar","year":"2009","unstructured":"Kumar H, Kumagai Y, Tsuchida T, Koenig PA, Satoh T, Guo Z, et al. Involvement of the NLRP3 inflammasome in innate and humoral adaptive immune responses to fungal beta-glucan. J Immunol. 2009;183:8061\u20137.","journal-title":"J Immunol"},{"key":"2379_CR25","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1161\/CIRCGENETICS.113.000381","volume":"7","author":"S Toldo","year":"2014","unstructured":"Toldo S, Das A, Mezzaroma E, Chau VQ, Marchetti C, Durrant D, et al. Induction of microRNA-21 with exogenous hydrogen sulfide attenuates myocardial ischemic and inflammatory injury in mice. Circ Cardiovasc Genet. 2014;7:311\u201320.","journal-title":"Circ Cardiovasc Genet"},{"key":"2379_CR26","doi-asserted-by":"publisher","first-page":"111418","DOI":"10.1016\/j.cellsig.2024.111418","volume":"124","author":"RL Silva","year":"2024","unstructured":"Silva RL, Lopes AH, Becerra A, Fonseca MM, Maganin A, Saraiva ALL, et al. Molecular mechanisms of zymosan-induced inflammasome activation in macrophages. Cell Signal. 2024;124:111418.","journal-title":"Cell Signal"},{"key":"2379_CR27","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1097\/FJC.0000000000000053","volume":"63","author":"C Marchetti","year":"2014","unstructured":"Marchetti C, Chojnacki J, Toldo S, Mezzaroma E, Tranchida N, Rose SW, et al. A novel pharmacologic inhibitor of the NLRP3 inflammasome limits myocardial injury after ischemia-reperfusion in the mouse. J Cardiovasc Pharmacol. 2014;63:316\u201322.","journal-title":"J Cardiovasc Pharmacol"},{"key":"2379_CR28","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s40265-025-02169-x","volume":"85","author":"A Bonaventura","year":"2025","unstructured":"Bonaventura A, Santagata D, Vecchie A, Abbate A. Current drug treatment for acute and recurrent pericarditis. Drugs. 2025;85:643\u201358.","journal-title":"Drugs"},{"key":"2379_CR29","doi-asserted-by":"publisher","first-page":"162","DOI":"10.7326\/0003-4819-86-2-162","volume":"86","author":"DG Wright","year":"1977","unstructured":"Wright DG, Wolff SM, Fauci AS, Alling DW. Efficacy of intermittent colchicine therapy in familial Mediterranean fever. Ann Intern Med. 1977;86:162\u20135.","journal-title":"Ann Intern Med"},{"key":"2379_CR30","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/S0140-6736(87)92641-9","volume":"2","author":"A Rodriguez de la Serna","year":"1987","unstructured":"Rodriguez de la Serna A, Guindo Soldevila J, Marti Claramunt V, Bayes de Luna A. Colchicine for recurrent pericarditis. Lancet. 1987;2:1517.","journal-title":"Lancet"},{"key":"2379_CR31","doi-asserted-by":"crossref","unstructured":"Guindo J, Rodriguez de la Serna A, Ramio J, de Miguel Diaz MA, Subirana MT, Perez Ayuso MJ, et al. Recurrent pericarditis. Relief with colchicine. Circulation. 1990;82:1117\u201320.","DOI":"10.1161\/01.CIR.82.4.1117"},{"key":"2379_CR32","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1161\/CIRCULATIONAHA.105.542738","volume":"112","author":"M Imazio","year":"2005","unstructured":"Imazio M, Bobbio M, Cecchi E, Demarie D, Demichelis B, Pomari F, et al. Colchicine in addition to conventional therapy for acute pericarditis: results of the COlchicine for acute PEricarditis (COPE) trial. Circulation. 2005;112:2012\u20136.","journal-title":"Circulation"},{"key":"2379_CR33","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1001\/archinte.165.17.1987","volume":"165","author":"M Imazio","year":"2005","unstructured":"Imazio M, Bobbio M, Cecchi E, Demarie D, Pomari F, Moratti M, et al. Colchicine as first-choice therapy for recurrent pericarditis: results of the CORE (COlchicine for REcurrent pericarditis) trial. Arch Intern Med. 2005;165:1987\u201391.","journal-title":"Arch Intern Med"},{"key":"2379_CR34","doi-asserted-by":"publisher","first-page":"409","DOI":"10.7326\/0003-4819-155-7-201110040-00359","volume":"155","author":"M Imazio","year":"2011","unstructured":"Imazio M, Brucato A, Cemin R, Ferrua S, Belli R, Maestroni S, et al. Colchicine for recurrent pericarditis (CORP): a randomized trial. Ann Intern Med. 2011;155:409\u201314.","journal-title":"Ann Intern Med"},{"key":"2379_CR35","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1056\/NEJMoa1208536","volume":"369","author":"M Imazio","year":"2013","unstructured":"Imazio M, Brucato A, Cemin R, Ferrua S, Maggiolini S, Beqaraj F, et al. A randomized trial of colchicine for acute pericarditis. N Engl J Med. 2013;369:1522\u20138.","journal-title":"N Engl J Med"},{"key":"2379_CR36","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1016\/S0140-6736(13)62709-9","volume":"383","author":"M Imazio","year":"2014","unstructured":"Imazio M, Belli R, Brucato A, Cemin R, Ferrua S, Beqaraj F, et al. Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial. Lancet. 2014;383:2232\u20137.","journal-title":"Lancet"},{"key":"2379_CR37","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s00059-002-2376-5","volume":"27","author":"Y Finkelstein","year":"2002","unstructured":"Finkelstein Y, Shemesh J, Mahlab K, Abramov D, Bar-El Y, Sagie A, et al. Colchicine for the prevention of postpericardiotomy syndrome. Herz. 2002;27:791\u20134.","journal-title":"Herz"},{"key":"2379_CR38","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1093\/eurheartj\/ehq319","volume":"31","author":"M Imazio","year":"2010","unstructured":"Imazio M, Trinchero R, Brucato A, Rovere ME, Gandino A, Cemin R, et al. COlchicine for the Prevention of the Post-pericardiotomy Syndrome (COPPS): a multicentre, randomized, double-blind, placebo-controlled trial. Eur Heart J. 2010;31:2749\u201354.","journal-title":"Eur Heart J"},{"key":"2379_CR39","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1001\/jama.2014.11026","volume":"312","author":"M Imazio","year":"2014","unstructured":"Imazio M, Brucato A, Ferrazzi P, Pullara A, Adler Y, Barosi A, et al. Colchicine for prevention of postpericardiotomy syndrome and postoperative atrial fibrillation: the COPPS-2 randomized clinical trial. JAMA. 2014;312:1016\u201323.","journal-title":"JAMA"},{"key":"2379_CR40","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.ahj.2010.06.015","volume":"160","author":"M Lotrionte","year":"2010","unstructured":"Lotrionte M, Biondi-Zoccai G, Imazio M, Castagno D, Moretti C, Abbate A, et al. International collaborative systematic review of controlled clinical trials on pharmacologic treatments for acute pericarditis and its recurrences. Am Heart J. 2010;160:662\u201370.","journal-title":"Am Heart J"},{"key":"2379_CR41","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.amjcard.2011.03.087","volume":"108","author":"M Imazio","year":"2011","unstructured":"Imazio M, Brucato A, Markel G, Cemin R, Trinchero R, Spodick DH, et al. Meta-analysis of randomized trials focusing on prevention of the postpericardiotomy syndrome. Am J Cardiol. 2011;108:575\u20139.","journal-title":"Am J Cardiol"},{"key":"2379_CR42","first-page":"1078","volume":"98","author":"M Imazio","year":"2012","unstructured":"Imazio M, Brucato A, Forno D, Ferro S, Belli R, Trinchero R, et al. Efficacy and safety of colchicine for pericarditis prevention. Systematic Rev Meta-Anal Heart. 2012;98:1078\u201382.","journal-title":"Systematic Rev Meta-Anal Heart"},{"key":"2379_CR43","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ijcard.2012.06.040","volume":"161","author":"M Alam","year":"2012","unstructured":"Alam M, Kayani WT, Bandeali SJ, Shahzad SA, Huang HD, Virani SS, et al. Impact of colchicine on pericardial inflammatory syndromes\u2013an analysis of randomized clinical trials. Int J Cardiol. 2012;161:59\u201362.","journal-title":"Int J Cardiol"},{"key":"2379_CR44","doi-asserted-by":"publisher","first-page":"840","DOI":"10.2459\/JCM.0000000000000103","volume":"15","author":"M Imazio","year":"2014","unstructured":"Imazio M, Brucato A, Belli R, Forno D, Ferro S, Trinchero R, et al. Colchicine for the prevention of pericarditis: what we know and what we do not know in 2014 - systematic review and meta-analysis. J Cardiovasc Med (Hagerstown). 2014;15:840\u20136.","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"2379_CR45","first-page":"CD010652","volume":"2014","author":"S Alabed","year":"2014","unstructured":"Alabed S, Cabello JB, Irving GJ, Qintar M, Burls A. Colchicine for pericarditis. Cochrane Database Syst Rev. 2014;2014:CD010652.","journal-title":"Cochrane Database Syst Rev"},{"key":"2379_CR46","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.hlc.2015.01.010","volume":"24","author":"J Raval","year":"2015","unstructured":"Raval J, Nagaraja V, Eslick GD, Denniss AR. The role of colchicine in pericarditis--a systematic review and meta-analysis of randomised trials. Heart Lung Circ. 2015;24:660\u20136.","journal-title":"Heart Lung Circ"},{"key":"2379_CR47","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1093\/ehjcvp\/pvv001","volume":"1","author":"SK Agarwal","year":"2015","unstructured":"Agarwal SK, Vallurupalli S, Uretsky BF, Hakeem A. Effectiveness of colchicine for the prevention of recurrent pericarditis and post-pericardiotomy syndrome: an updated meta-analysis of randomized clinical data. Eur Heart J Cardiovasc Pharmacother. 2015;1:117\u201325.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2379_CR48","doi-asserted-by":"publisher","first-page":"144","DOI":"10.2459\/JCM.0000000000000237","volume":"16","author":"A Briasoulis","year":"2015","unstructured":"Briasoulis A, Afonso L. Prevention of pericarditis with colchicine: an updated meta-analysis. J Cardiovasc Med (Hagerstown). 2015;16:144\u20137.","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"2379_CR49","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1007\/s00059-016-4410-z","volume":"41","author":"YL Li","year":"2016","unstructured":"Li YL, Qiao SB, Wang JY, Chen YM, Luo J, Zhang HF. Colchicine in addition to conventional therapy for pericarditis recurrence: an update meta-analysis. Herz. 2016;41:630\u20138.","journal-title":"Herz"},{"key":"2379_CR50","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/1755-5922.12226","volume":"35","author":"N Papageorgiou","year":"2017","unstructured":"Papageorgiou N, Briasoulis A, Lazaros G, Imazio M, Tousoulis D. Colchicine for prevention and treatment of cardiac diseases: a meta-analysis. Cardiovasc Ther. 2017;35:10\u20138.","journal-title":"Cardiovasc Ther"},{"key":"2379_CR51","doi-asserted-by":"publisher","first-page":"314","DOI":"10.23736\/S0031-0808.21.04263-4","volume":"63","author":"S Avondo","year":"2021","unstructured":"Avondo S, Andreis A, Casula M, Biondi-Zoccai G, Imazio M. Pharmacologic treatment of acute and recurrent pericarditis: a systematic review and meta-analysis of controlled clinical trials. Panminerva Med. 2021;63:314\u201323.","journal-title":"Panminerva Med"},{"key":"2379_CR52","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.tcm.2022.02.001","volume":"33","author":"M Melendo-Viu","year":"2023","unstructured":"Melendo-Viu M, Marchan-Lopez A, Guarch CJ, Roubin SR, Abu-Assi E, Meneses RT, et al. A systematic review and meta-analysis of randomized controlled trials evaluating pharmacologic therapies for acute and recurrent pericarditis. Trends Cardiovasc Med. 2023;33:319\u201326.","journal-title":"Trends Cardiovasc Med"},{"key":"2379_CR53","doi-asserted-by":"publisher","first-page":"e041007","DOI":"10.1161\/JAHA.125.041007","volume":"14","author":"M Ehsan","year":"2025","unstructured":"Ehsan M, Syed AB, Mustafa B, Ikram J, Khan MH, Cremer PC, et al. Comparative Efficacy and Safety of Colchicine and Anti-Interleukin-1 Agents in Recurrent Pericarditis: A Pairwise and Network Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc. 2025;14:e041007.","journal-title":"J Am Heart Assoc"},{"key":"2379_CR54","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1002\/art.24174","volume":"60","author":"P Picco","year":"2009","unstructured":"Picco P, Brisca G, Traverso F, Loy A, Gattorno M, Martini A. Successful treatment of idiopathic recurrent pericarditis in children with interleukin-1beta receptor antagonist (Anakinra): an unrecognized autoinflammatory disease? Arthritis Rheum. 2009;60:264\u20138.","journal-title":"Arthritis Rheum"},{"key":"2379_CR55","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ijcard.2012.05.086","volume":"160","author":"D Vassilopoulos","year":"2012","unstructured":"Vassilopoulos D, Lazaros G, Tsioufis C, Vasileiou P, Stefanadis C, Pectasides D. Successful treatment of adult patients with idiopathic recurrent pericarditis with an interleukin-1 receptor antagonist (Anakinra). Int J Cardiol. 2012;160:66\u20138.","journal-title":"Int J Cardiol"},{"key":"2379_CR56","doi-asserted-by":"crossref","unstructured":"Lazaros G, Vasileiou P, Koutsianas C, Antonatou K, Stefanadis C, Pectasides D, et al. Anakinra for the management of resistant idiopathic recurrent pericarditis. Initial experience in 10 adult cases. Ann Rheum Dis. 2014;73:2215\u20137.","DOI":"10.1136\/annrheumdis-2014-205990"},{"key":"2379_CR57","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/j.jpeds.2014.01.065","volume":"164","author":"M Finetti","year":"2014","unstructured":"Finetti M, Insalaco A, Cantarini L, Meini A, Breda L, Alessio M, et al. Long-term efficacy of interleukin-1 receptor antagonist (Anakinra) in corticosteroid-dependent and colchicine-resistant recurrent pericarditis. J Pediatr. 2014;164:1425-31 e1.","journal-title":"J Pediatr"},{"key":"2379_CR58","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/j.amjcard.2015.07.047","volume":"116","author":"S Jain","year":"2015","unstructured":"Jain S, Thongprayoon C, Espinosa RE, Hayes SN, Klarich KW, Cooper LT, et al. Effectiveness and Safety of Anakinra for Management of Refractory Pericarditis. Am J Cardiol. 2015;116:1277\u20139.","journal-title":"Am J Cardiol"},{"key":"2379_CR59","first-page":"888","volume":"9","author":"MH Shaukat","year":"2020","unstructured":"Shaukat MH, Singh S, Davis K, Torosoff M, Peredo-Wende R. Efficacy of anakinra for idiopathic and non-idiopathic pericarditis refractory or intolerant to conventional therapy. Eur Heart J Acute Cardiovasc Care. 2020;9:888\u201392.","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"2379_CR60","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1097\/FJC.0000000000000839","volume":"76","author":"ETO Correia","year":"2020","unstructured":"Correia ETO, Dos Santos Barbetta LM, de Almeida J, Mesquita ET. Anakinra in recurrent pericarditis: current evidence on clinical use, effectiveness, and safety. J Cardiovasc Pharmacol. 2020;76:42\u20139.","journal-title":"J Cardiovasc Pharmacol"},{"key":"2379_CR61","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1097\/FJC.0000000000000847","volume":"76","author":"GF Wohlford","year":"2020","unstructured":"Wohlford GF, Buckley LF, Vecchie A, Kadariya D, Markley R, Trankle CR, et al. Acute Effects of Interleukin-1 Blockade Using Anakinra in Patients With Acute Pericarditis. J Cardiovasc Pharmacol. 2020;76:50\u20132.","journal-title":"J Cardiovasc Pharmacol"},{"key":"2379_CR62","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1177\/2047487319879534","volume":"27","author":"M Imazio","year":"2020","unstructured":"Imazio M, Andreis A, De Ferrari GM, Cremer PC, Mardigyan V, Maestroni S, et al. Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: The IRAP (International Registry of Anakinra for Pericarditis) study. Eur J Prev Cardiol. 2020;27:956\u201364.","journal-title":"Eur J Prev Cardiol"},{"key":"2379_CR63","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1136\/heartjnl-2020-316898","volume":"106","author":"A Andreis","year":"2020","unstructured":"Andreis A, Imazio M, Giustetto C, Brucato A, Adler Y, De Ferrari GM. Anakinra for constrictive pericarditis associated with incessant or recurrent pericarditis. Heart. 2020;106:1561\u20135.","journal-title":"Heart"},{"key":"2379_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.612259","volume":"11","author":"C Carnovale","year":"2020","unstructured":"Carnovale C, Tombetti E, Battini V, Mazhar F, Radice S, Nivuori M, et al. Inflammasome Targeted Therapy in Pregnancy: New Insights From an Analysis of Real-World Data From the FAERS Database and a Systematic Review. Front Pharmacol. 2020;11:612259.","journal-title":"Front Pharmacol"},{"key":"2379_CR65","doi-asserted-by":"publisher","first-page":"114553","DOI":"10.1016\/j.ejogrb.2025.114553","volume":"312","author":"L Trotta","year":"2025","unstructured":"Trotta L, Mascolo R, Mardygan V, Cercek AC, Claveau AM, Sicignano LL, et al. Use of anakinra during pregnancy and breastfeeding in women with recurrent pericarditis: a case series. Eur J Obstet Gynecol Reprod Biol. 2025;312:114553.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2379_CR66","doi-asserted-by":"publisher","first-page":"e032516","DOI":"10.1161\/JAHA.123.032516","volume":"13","author":"M Imazio","year":"2024","unstructured":"Imazio M, Klein AL, Brucato A, Abbate A, Arad M, Cremer PC, et al. Sustained Pericarditis Recurrence Risk Reduction With Long-Term Rilonacept. J Am Heart Assoc. 2024;13:e032516.","journal-title":"J Am Heart Assoc"},{"key":"2379_CR67","doi-asserted-by":"crossref","unstructured":"Imazio M, Trotta L, Bizzi E, Pancrazi M, Wang S, Clair J, et al. Multi-year recurrent pericarditis disease duration in Italian patients: clinical outcomes after cessation of long-term IL-1 pathway inhibition provide insights for chronic management. Eur Heart J. 2024;45(Issue Supplement_1):ehae666.2104.","DOI":"10.1093\/eurheartj\/ehae666.2104"},{"key":"2379_CR68","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.cjco.2024.02.002","volume":"6","author":"A Brucato","year":"2024","unstructured":"Brucato A, Trotta L, Arad M, Cremer PC, Insalaco A, Klutstein M, et al. Absence of pericarditis recurrence in rilonacept-treated patients with COVID-19 and SARS-CoV-2 vaccination: results from the RHAPSODY long-term extension. CJC Open. 2024;6:805\u201310.","journal-title":"CJC Open"},{"key":"2379_CR69","doi-asserted-by":"publisher","first-page":"e023252","DOI":"10.1161\/JAHA.121.023252","volume":"11","author":"A Brucato","year":"2022","unstructured":"Brucato A, Lim-Watson MZ, Klein A, Imazio M, Cella D, Cremer P, et al. Interleukin-1 Trap Rilonacept Improved Health-Related Quality of Life and Sleep in Patients With Recurrent Pericarditis: Results From the Phase 3 Clinical Trial RHAPSODY. J Am Heart Assoc. 2022;11:e023252.","journal-title":"J Am Heart Assoc"},{"key":"2379_CR70","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1136\/heartjnl-2022-321328","volume":"109","author":"A Brucato","year":"2023","unstructured":"Brucato A, Wheeler A, Luis SA, Abbate A, Cremer PC, Zou L, et al. Transition to rilonacept monotherapy from oral therapies in patients with recurrent pericarditis. Heart. 2023;109:297\u2013304.","journal-title":"Heart"},{"key":"2379_CR71","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1161\/CIRCULATIONAHA.124.069396","volume":"150","author":"A Abbate","year":"2024","unstructured":"Abbate A, Van Tassell B, Bogin V, Markley R, Pevzner DV, Cremer PC, et al. Results of International, Double-Blind, Randomized, Placebo-Controlled, Phase IIa Study of Interleukin-1 Blockade With RPH-104 (Goflikicept) in Patients With ST-Segment-Elevation Myocardial Infarction (STEMI). Circulation. 2024;150:580\u20132.","journal-title":"Circulation"},{"key":"2379_CR72","first-page":"180","volume":"42","author":"MB Bridgeman","year":"2017","unstructured":"Bridgeman MB, Abazia DT. Medicinal cannabis: history, pharmacology, and implications for the acute care setting. P T. 2017;42:180\u20138.","journal-title":"P T"},{"key":"2379_CR73","doi-asserted-by":"publisher","first-page":"5980","DOI":"10.3390\/molecules28165980","volume":"28","author":"N Martinez Naya","year":"2023","unstructured":"Martinez Naya N, Kelly J, Corna G, Golino M, Abbate A, Toldo S. Molecular and Cellular Mechanisms of Action of Cannabidiol. Mol. 2023;28:5980.","journal-title":"Molecules"},{"key":"2379_CR74","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1080\/13543784.2024.2351513","volume":"33","author":"NM Naya","year":"2024","unstructured":"Naya NM, Kelly J, Hogwood A, Abbate A, Toldo S. Therapeutic potential of cannabidiol (CBD) in the treatment of cardiovascular diseases. Expert Opin Investig Drugs. 2024;33:699\u2013712.","journal-title":"Expert Opin Investig Drugs"},{"key":"2379_CR75","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20081833","author":"A Mabou Tagne","year":"2019","unstructured":"Mabou Tagne A, Marino F, Legnaro M, Luini A, Pacchetti B, Cosentino M. A novel standardized Cannabis sativa L. extract and its constituent cannabidiol inhibit human polymorphonuclear leukocyte functions. Int J Mol Sci. 2019. https:\/\/doi.org\/10.3390\/ijms20081833.","journal-title":"Int J Mol Sci"},{"key":"2379_CR76","doi-asserted-by":"publisher","DOI":"10.3390\/ph14030220","author":"CT Gomez","year":"2021","unstructured":"Gomez CT, Lairion F, Repetto M, Ettcheto M, Merelli A, Lazarowski A, et al. Cannabidiol (CBD) alters the functionality of neutrophils (PMN). Implications in the refractory epilepsy treatment. Pharmaceuticals (Basel). 2021. https:\/\/doi.org\/10.3390\/ph14030220.","journal-title":"Pharmaceuticals (Basel)"},{"key":"2379_CR77","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.taap.2007.09.012","volume":"226","author":"HY Wu","year":"2008","unstructured":"Wu HY, Chu RM, Wang CC, Lee CY, Lin SH, Jan TR. Cannabidiol-induced apoptosis in primary lymphocytes is associated with oxidative stress-dependent activation of caspase-8. Toxicol Appl Pharmacol. 2008;226:260\u201370.","journal-title":"Toxicol Appl Pharmacol"},{"key":"2379_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cellimm.2018.02.016","volume":"329","author":"H Li","year":"2018","unstructured":"Li H, Kong W, Chambers CR, Yu D, Ganea D, Tuma RF, et al. The non-psychoactive phytocannabinoid cannabidiol (CBD) attenuates pro-inflammatory mediators, T cell infiltration, and thermal sensitivity following spinal cord injury in mice. Cell Immunol. 2018;329:1\u20139.","journal-title":"Cell Immunol"},{"key":"2379_CR79","unstructured":"Naya NLM, Nirar AH, Kim MM, Mauro AG, Mezzaroma E, Narayan P, et al. Protective effects of cannabidiol in a mouse model of acute pericarditis. Circulation Research. 2022;e169\u2013e190."},{"key":"2379_CR80","unstructured":"Naya NM, Kelly J, Mezzaroma E, Mauro GA, Hamer A, Bolton J, et al. Cannabidiol inhibits the mesothelial to mesenchymal transition in experimental pericarditis. Poster presented at the 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases; Accessible at https:\/\/www.cardiolrx.com\/wp-content\/uploads\/2023\/11\/Cannabidiol-inhibits-the-mesothelial-to-mesenchymal-transition-in-experimental-pericarditis_MPD2023-1.pdf."},{"key":"2379_CR81","doi-asserted-by":"publisher","DOI":"10.1161\/circ.150.suppl_1.4140774","volume":"150","author":"S Luis","year":"2024","unstructured":"Luis S, Klein A, Cremer P, Abbate A, Salik J, Thomas G, et al. Abstract 4140774: Pharmaceutically manufactured cannabidiol demonstrates clinically relevant reductions in pericarditis pain and C-Reactive Protein in patients with recurrent pericarditis \u2013 the MAvERIC-Pilot Study. Circulation. 2024;150:A4140774-A.","journal-title":"Circulation"},{"key":"2379_CR82","unstructured":"Cannabidiol Formulation Granted Orphan Drug Designation for Pericarditis. https:\/\/www.empr.com\/home\/news\/drugs-in-the-pipeline\/cannabidiol-formulation-granted-orphan-drug-designation-for-pericarditis\/. Accessed on November 3rd 2025."},{"key":"2379_CR83","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1097\/HCO.0000000000001201","volume":"40","author":"AB Raisinghani","year":"2025","unstructured":"Raisinghani AB, Luis SA. Treatment options to break the cycle of recurrent pericarditis. Curr Opin Cardiol. 2025;40:107\u201314.","journal-title":"Curr Opin Cardiol"},{"key":"2379_CR84","doi-asserted-by":"publisher","first-page":"249","DOI":"10.23736\/S0031-0808.20.04205-6","volume":"63","author":"A Bonaventura","year":"2021","unstructured":"Bonaventura A, Vecchie A, Mauro AG, Brucato AL, Imazio M, Abbate A. An update on the pathophysiology of acute and recurrent pericarditis. Panminerva Med. 2021;63:249\u201360.","journal-title":"Panminerva Med"},{"key":"2379_CR85","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1080\/14656566.2022.2054327","volume":"23","author":"A Vecchie","year":"2022","unstructured":"Vecchie A, Del Buono MG, Mauro AG, Cremer PC, Imazio M, Klein AL, et al. Advances in pharmacotherapy for acute and recurrent pericarditis. Expert Opin Pharmacother. 2022;23:681\u201391.","journal-title":"Expert Opin Pharmacother"},{"key":"2379_CR86","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/nrd3800","volume":"11","author":"CA Dinarello","year":"2012","unstructured":"Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov. 2012;11:633\u201352.","journal-title":"Nat Rev Drug Discov"},{"key":"2379_CR87","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/eji.201040319","volume":"40","author":"CA Dinarello","year":"2010","unstructured":"Dinarello CA. IL-1: discoveries, controversies and future directions. Eur J Immunol. 2010;40:599\u2013606.","journal-title":"Eur J Immunol"},{"key":"2379_CR88","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1016\/j.chest.2020.07.039","volume":"158","author":"A Vecchie","year":"2020","unstructured":"Vecchie A, Chiabrando JG, Dell MS, Bonaventura A, Mauro AG, Wohlford G, et al. Clinical Presentation and Outcomes of Acute Pericarditis in a Large Urban Hospital in the United States of America. Chest. 2020;158:2556\u201367.","journal-title":"Chest"},{"key":"2379_CR89","doi-asserted-by":"publisher","DOI":"10.1111\/eci.14110","volume":"54","author":"MG Del Buono","year":"2024","unstructured":"Del Buono MG, Bonaventura A, Vecchie A, Moroni F, Golino M, Bressi E, et al. Pathogenic pathways and therapeutic targets of inflammation in heart diseases: A focus on Interleukin-1. Eur J Clin Invest. 2024;54:e14110.","journal-title":"Eur J Clin Invest"},{"key":"2379_CR90","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ejim.2023.03.034","volume":"113","author":"AM Pisacreta","year":"2023","unstructured":"Pisacreta AM, Mascolo R, Nivuori M, Dominioni CC, Gabiati C, Trotta L, et al. Acute pericarditis with pleuropulmonary involvement, fever and elevated C-reactive protein: A systemic autoinflammatory disease? A cohort study. Eur J Intern Med. 2023;113:45\u20138.","journal-title":"Eur J Intern Med"},{"key":"2379_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2024.132945","volume":"423","author":"M Imazio","year":"2025","unstructured":"Imazio M, Brucato A, Lazaros G, Andreis A, Mascolo R, Berra S, et al. Outcomes of acute pericarditis with an inflammatory phenotype. Int J Cardiol. 2025;423:132945.","journal-title":"Int J Cardiol"},{"key":"2379_CR92","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/jamacardio.2023.4820","volume":"9","author":"RB Thorolfsdottir","year":"2024","unstructured":"Thorolfsdottir RB, Jonsdottir AB, Sveinbjornsson G, Aegisdottir HM, Oddsson A, Stefansson OA, et al. Variants at the Interleukin 1 Gene Locus and Pericarditis. JAMA Cardiol. 2024;9:165\u201372.","journal-title":"JAMA Cardiol"},{"key":"2379_CR93","doi-asserted-by":"publisher","first-page":"e024931","DOI":"10.1161\/JAHA.121.024931","volume":"11","author":"CJ Peet","year":"2022","unstructured":"Peet CJ, Rowczenio D, Omoyinmi E, Papadopoulou C, Mapalo BRR, Wood MR, et al. Pericarditis and Autoinflammation: A Clinical and Genetic Analysis of Patients With Idiopathic Recurrent Pericarditis and Monogenic Autoinflammatory Diseases at a National Referral Center. J Am Heart Assoc. 2022;11:e024931.","journal-title":"J Am Heart Assoc"},{"key":"2379_CR94","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2459\/JCM.0000000000001669","volume":"25","author":"M Imazio","year":"2024","unstructured":"Imazio M, Faletra F, Zucco J, Mio C, Carraro M, Gava AM, et al. Genetic variants in patients with recurrent pericarditis. J Cardiovasc Med (Hagerstown). 2024;25:799\u2013804.","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"2379_CR95","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13206051","author":"A Andreis","year":"2024","unstructured":"Andreis A, Dossi FC, De Ferrari GM, Alunni G, Imazio M. Anakinra-dependent recurrent pericarditis: The role of the R202Q variant of the MEFV gene. J Clin Med. 2024. https:\/\/doi.org\/10.3390\/jcm13206051.","journal-title":"J Clin Med"},{"key":"2379_CR96","doi-asserted-by":"publisher","first-page":"102050","DOI":"10.1016\/j.jacadv.2025.102050","volume":"4","author":"PC Cremer","year":"2025","unstructured":"Cremer PC, Luis SA, Garshick MS, Raisinghani A, Weber B, Winnowski D, et al. IL-1 Pathway Inhibition in Recurrent Pericarditis Management: Real-World Adoption of Corticosteroid Sparing in RESONANCE. JACC Adv. 2025;4:102050.","journal-title":"JACC Adv"},{"key":"2379_CR97","unstructured":"Ventyx Biosciences Announces Positive Topline Results from Phase 2 Study of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors. https:\/\/ir.ventyxbio.com\/news-releases\/news-release-details\/ventyx-biosciences-announces-positive-topline-results-phase-2. Accessed on November 10th 2025."},{"key":"2379_CR98","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/nature16959","volume":"530","author":"Y He","year":"2016","unstructured":"He Y, Zeng MY, Yang D, Motro B, Nunez G. NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux. Nature. 2016;530:354\u20137.","journal-title":"Nature"},{"key":"2379_CR99","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adl2993","volume":"10","author":"J Xu","year":"2025","unstructured":"Xu J, Zhang L, Duan Y, Sun F, Odeh N, He Y, et al. NEK7 phosphorylation amplifies NLRP3 inflammasome activation downstream of potassium efflux and gasdermin D. Sci Immunol. 2025;10:eadl2993.","journal-title":"Sci Immunol"},{"key":"2379_CR100","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1001\/jama.2024.12935","volume":"332","author":"PC Cremer","year":"2024","unstructured":"Cremer PC, Klein AL, Imazio M. Diagnosis, risk stratification, and treatment of pericarditis: a review. JAMA. 2024;332:1090\u2013100.","journal-title":"JAMA"},{"key":"2379_CR101","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.jacc.2003.08.032","volume":"43","author":"JH Haley","year":"2004","unstructured":"Haley JH, Tajik AJ, Danielson GK, Schaff HV, Mulvagh SL, Oh JK. Transient constrictive pericarditis: causes and natural history. J Am Coll Cardiol. 2004;43:271\u20135.","journal-title":"J Am Coll Cardiol"},{"key":"2379_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2023.131225","volume":"390","author":"A Baritussio","year":"2023","unstructured":"Baritussio A, Giordani AS, Iliceto S, Marcolongo R, Caforio ALP. Transient pericardial constriction: a not so rare entity. Int J Cardiol. 2023;390:131225.","journal-title":"Int J Cardiol"},{"key":"2379_CR103","first-page":"294","volume":"33","author":"E D'Elia","year":"2015","unstructured":"D\u2019Elia E, Brucato A, Pedrotti P, Valenti A, De Amici M, Fiocca L, et al. Successful treatment of subacute constrictive pericarditis with interleukin-1beta receptor antagonist (anakinra). Clin Exp Rheumatol. 2015;33:294\u20135.","journal-title":"Clin Exp Rheumatol"},{"key":"2379_CR104","first-page":"945","volume":"33","author":"G Lazaros","year":"2015","unstructured":"Lazaros G, Vasileiou P, Danias P, Koutsianas C, Vlachopoulos C, Tousoulis D, et al. Effusive-constrictive pericarditis successfully treated with anakinra. Clin Exp Rheumatol. 2015;33:945.","journal-title":"Clin Exp Rheumatol"},{"key":"2379_CR105","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ijcard.2016.08.131","volume":"223","author":"A Schatz","year":"2016","unstructured":"Schatz A, Trankle C, Yassen A, Chipko C, Rajab M, Abouzaki N, et al. Resolution of pericardial constriction with Anakinra in a patient with effusive-constrictive pericarditis secondary to rheumatoid arthritis. Int J Cardiol. 2016;223:215\u20136.","journal-title":"Int J Cardiol"},{"key":"2379_CR106","first-page":"1854","volume":"100","author":"G Pathangey","year":"2025","unstructured":"Pathangey G, Narayanasamy H, Marcotte F, Luis SA, Ayoub C. Interleukin 1 inhibition for constrictive pericarditis: a novel therapeutic approach. Mayo Clin Proc. 2025;100:1854\u20136.","journal-title":"Mayo Clin Proc"},{"key":"2379_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccas.2025.105348","volume":"30","author":"P Creechan","year":"2025","unstructured":"Creechan P, Lockwood M, Weber BN, Klein A, Haider SW. Use of an IL-1 inhibitor for refractory steroid-dependent lupus pericarditis with constrictive physiology. JACC Case Rep. 2025;30:105348.","journal-title":"JACC Case Rep"},{"key":"2379_CR108","first-page":"454","volume":"112","author":"U Saraswati","year":"2026","unstructured":"Saraswati U, Bhalla JS, Tereshchenko LG, Heine M, Syed AB, Wang TKM, et al. Comparative analysis of recurrence rates following various cessation strategies for rilonacept in recurrent pericarditis. Heart. 2026;112:454\u201361.","journal-title":"Heart"},{"key":"2379_CR109","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2026.102774","author":"M Marchetta","year":"2026","unstructured":"Marchetta M, Thomas G, Golino M, Cutts JA, Pan JA, Lopez RI, et al. Interleukin-1 blockade with Rilonacept in recurrent pericarditis. JACC Adv. 2026;5(5):102774. https:\/\/doi.org\/10.1016\/j.jacadv.2026.102774","journal-title":"JACC Adv"},{"key":"2379_CR110","doi-asserted-by":"publisher","first-page":"e2536691","DOI":"10.1001\/jamanetworkopen.2025.36691","volume":"8","author":"MA Wu","year":"2025","unstructured":"Wu MA, Kessel C, Fadle N, Regitz E, Fuehner S, Negro E, et al. IL-1 Receptor Antagonist Antibodies in Idiopathic Recurrent Pericarditis. JAMA Netw Open. 2025;8:e2536691.","journal-title":"JAMA Netw Open"},{"key":"2379_CR111","doi-asserted-by":"publisher","first-page":"101194","DOI":"10.1016\/j.jacadv.2024.101194","volume":"3","author":"R Karmali","year":"2024","unstructured":"Karmali R, Kafil TS, Bayat A, Honnekeri B, Badwan O, Berglund F, et al. Recurrent pericarditis and paradigm shift in cardiovascular imaging and targeted therapeutics. JACC Adv. 2024;3:101194.","journal-title":"JACC Adv"},{"key":"2379_CR112","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1136\/heartjnl-2020-317928","volume":"107","author":"AL Klein","year":"2020","unstructured":"Klein AL, Lin D, Cremer PC, Nasir S, Luis SA, Abbate A, et al. Efficacy and safety of rilonacept for recurrent pericarditis: results from a phase II clinical trial. Heart. 2020;107:488\u201396.","journal-title":"Heart"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-026-02379-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-026-02379-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-026-02379-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T10:02:28Z","timestamp":1779789748000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11886-026-02379-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":112,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2379"],"URL":"https:\/\/doi.org\/10.1007\/s11886-026-02379-z","relation":{},"ISSN":["1534-3170"],"issn-type":[{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]},"assertion":[{"value":"10 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MGDB served a consultant for Ventyx. BNW was supported by the NIH\/NHLBI (K23HL159276) and reports scientific advisory board roles or consulting from Novo Nordisk, Kiniksa, and BMS. ST has been a consultant for Cardiol Therapeutics and received investigator-initiated awards from Cardiol Therapeutics and Kiniksa. AA has served as a consultant for Kiniksa, Monte Rosa Therapeutics, Novo Nordisk, and Ventyx. The other authors have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Conflicts<!--Emphasis Type='Bold' removed--> of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"58"}}